Guildford, UK, 21 September 2010: ReNeuron Group plc (LSE: RENE.L) announces that it is presenting at a key UK regenerative medicine conference.  The conference, “Exploiting Market Opportunities in Regenerative Medicine” has been organised by the Technology Strategy Board (a body sponsored by the UK Government’s Department of Business, Innovation and Skills) and is taking place today at the King’s Fund, Cavendish Square, London.   

The conference will showcase the winners of the TSB’s recent regenerative medicine therapeutics feasibility studies grant competition and will be attended by representatives from the funding community, large pharma and the NHS.  Presenters will focus on how they have benefited from this funding to assist in addressing key challenges in the regenerative medicine field (such as formulation and delivery, scale-up and manufacturing and preparation for clinical trials) and the resulting commercial opportunities.  

Dr John Sinden, Chief Scientific Officer of ReNeuron, and Dr Kenny Pollock, Head of Cell Development, will describe how ReNeuron has deployed its two grant awards under the scheme to successfully complete the remaining steps to commencement of its ground-breaking UK Phase I clinical trial for its ReN001 stem cell therapy for disabled stroke patients, as well as progressing certain late pre-clinical activities with its ReN009 therapy for peripheral arterial disease.

Further information about the conference may be found at:


Michael Hunt, Chief Executive Officer – ReNeuron       +44 (0) 1483 302560
Dr John Sinden, Chief Scientific Officer – ReNeuron
Lisa Baderoon, Mark Court, Isabel Podda
Buchanan Communications                          +44 (0) 20 7466 5000

Emma Earl, Oliver Rigby
Daniel Stewart & Company plc                      +44 (0) 20 7776 6550

Alastair Stratton, Tim Graham
Matrix Corporate Capital LLP                       +44 (0) 20 3206 7000

About the Technology Strategy Board

The Technology Strategy Board is a business-led, executive non-departmental public body, established by the UK government.  Its role is to promote and support research into, and development and exploitation of, technology and innovation for the benefit of UK business, in order to increase economic growth and improve the quality of life.  It is sponsored by the Department for Business, Innovation and Skills (BIS).  Further information can be found at

About ReNeuron
ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.   

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron’s lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. A ground-breaking first-in-man clinical trial of ReN001 has recently commenced in the UK.  ReNeuron’s ReN009 stem cell therapy is being developed as a treatment for peripheral arterial disease, a serious and common side-effect of diabetes. The Company is also developing stem cell therapies for other conditions such as blindness-causing diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell® products for use in academic and commercial research.  The Company’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as “should”, “expects”, “estimates”, “believes” or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron’s current expectations and assumptions as to future events and circumstances that may not prove accurate.  A number of factors could cause ReNeuron’s actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.